Michel Gardet
Direttore/Membro del Consiglio presso Phagenesis Ltd.
Profilo
Michel Gardet is currently a Director at Phagenesis Ltd.
He was formerly a Director at Glycom A and Global Head-Business Operations at Nestle Health Science SA.
Posizioni attive di Michel Gardet
Società | Posizione | Inizio |
---|---|---|
Phagenesis Ltd.
Phagenesis Ltd. Pharmaceuticals: MajorHealth Technology Phagenesis Ltd. develops a treatment for dysphagia. Its product Phagenyx consists of a base station and a treatment catheter which in combination enable the healthcare professional to deliver personalized dysphagia treatment for every patient. The company was founded by Conor Joseph Mulrooney and Shaheen Hamdy in 2007 and is headquartered in Manchester, the United Kingdom. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Michel Gardet
Società | Posizione | Fine |
---|---|---|
Nestle Health Science SA
Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland. | Direttore operativo | - |
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Health Technology |
Nestle Health Science SA
Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland. | Health Technology |
Phagenesis Ltd.
Phagenesis Ltd. Pharmaceuticals: MajorHealth Technology Phagenesis Ltd. develops a treatment for dysphagia. Its product Phagenyx consists of a base station and a treatment catheter which in combination enable the healthcare professional to deliver personalized dysphagia treatment for every patient. The company was founded by Conor Joseph Mulrooney and Shaheen Hamdy in 2007 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Michel Gardet